Investigational drug · Phase 2
QHL-1618
Also called: ALK-N001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Gastrointestinal Tumors, Advanced Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "QHL-1618"
First trial start
2026
Apr 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QHL-1618", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Gastrointestinal Tumors
- Advanced Solid Tumors
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "QHL-1618" as an intervention, largest first.
- A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid TumorsNot yet recruiting
Zhejiang Anglikang Pharmaceutical Co., Ltd.Industry
NCT07509684 · 190 participants (planned) · Start Apr 2026 · Primary completion Dec 2027
Drug: ALK-N001 for Injection · For: Advanced Solid Tumors
- A Phase IIa Study Evaluating Injectable ALK-N001 in Patients With Advanced Gastrointestinal TumorsNot yet recruiting
Zhejiang Anglikang Pharmaceutical Co., Ltd.Industry
NCT07826195 · 174 participants (planned) · Start Sep 2026 · Primary completion Dec 2027
Drug: Injectable ALK-N001 · For: Advanced Gastrointestinal Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.Industry
NCT07529535 · 16 participants · Start Jun 5, 2025 · Primary completion Dec 2026
Drug: ALK-N001 for Injection · For: Advance Solid Tumors
Sites: Hangzhou, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.